<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04892537</url>
  </required_header>
  <id_info>
    <org_study_id>20HH6457</org_study_id>
    <secondary_id>MR/V001620/1</secondary_id>
    <nct_id>NCT04892537</nct_id>
  </id_info>
  <brief_title>Coronary Sinus Reducer Objective Impact on Symptoms, MRI Ischaemia and Microvascular Resistance</brief_title>
  <acronym>ORBITA-COSMIC</acronym>
  <official_title>Coronary Sinus Reducer Objective Impact on Symptoms, MRI Ischaemia and Microvascular Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ORBITA-COSMIC is a randomised, double-blinded, placebo controlled trial of the coronary sinus&#xD;
      reducer (CSR). The investigators will compare the effects of CSR versus placebo on myocardial&#xD;
      perfusion on MRI, exercise time and symptoms in 40 participants with refractory angina and&#xD;
      ischaemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Myocardial Perfusion Reserve on MRI between the groups</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in coronary resistance on pressure/temperature wire assessment between the groups</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in absolute coronary flow on pressure/temperature wire assessment between the groups</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in treadmill exercise time between the groups</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in angina frequency recorded on a smartphone symptom application between the groups</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physical limitation as assessed with the Seattle Angina Questionnaire between the groups</measure>
    <time_frame>6 months</time_frame>
    <description>On a scale from 0-100, with higher scores indicating better outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in angina stability as assessed with the Seattle Angina Questionnaire between the groups</measure>
    <time_frame>6 months</time_frame>
    <description>On a scale from 0-100, with higher scores indicating better outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life as assessed with the Seattle Angina Questionnaire between the groups</measure>
    <time_frame>6 months</time_frame>
    <description>On a scale from 0-100, with higher scores indicating better outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in angina frequency as assessed with the Seattle Angina Questionnaire between the groups</measure>
    <time_frame>6 months</time_frame>
    <description>On a scale from 0-100, with higher scores indicating better outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in freedom from angina as assessed with the Seattle Angina Questionnaire between the groups</measure>
    <time_frame>6 months</time_frame>
    <description>Binary outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life as assessed with the EQ-5D-5L questionnaire visual analogue scale between the groups</measure>
    <time_frame>6 months</time_frame>
    <description>Visual analogue scale from 0-100 with 100 indicating better quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life health state index as assessed with the EQ-5D-5L questionnaire between the groups</measure>
    <time_frame>6 months</time_frame>
    <description>Index derived from 5 question domains, with higher scores indicating better quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health related quality of life as assessed with the MacNew questionnaire between the groups</measure>
    <time_frame>6 months</time_frame>
    <description>On a scale from 1-7 with higher scores indicating better quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Canadian Cardiovascular Society (CCS) Class between the groups</measure>
    <time_frame>6 months</time_frame>
    <description>On a scale from 0-4 with higher score indicating more severe angina</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average daily steps measured on a smartwatch between the groups</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Refractory Angina</condition>
  <arm_group>
    <arm_group_label>CSR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coronary Sinus Reducer implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coronary Sinus Reducer</intervention_name>
    <description>Coronary Sinus Reducer implantation according to standard clinical protocols</description>
    <arm_group_label>CSR</arm_group_label>
    <other_name>CSR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Placebo Procedure</intervention_name>
    <description>A placebo procedure involving venous sheath implantation in the right internal jugular vein without proceeding to CSR implantation</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stable coronary artery disease (CAD) not eligible for percutaneous coronary&#xD;
             intervention (PCI) or coronary artery bypass graft surgery (CABG)&#xD;
&#xD;
          -  Evidence of ischaemia on stress perfusion CMR&#xD;
&#xD;
          -  Angina - Canadian Cardiovascular Society Class II-VI on maximal medical therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age&lt;18 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Inability to consent&#xD;
&#xD;
          -  Recent acute coronary syndrome (3 months)&#xD;
&#xD;
          -  Recent revascularisation (6 months)&#xD;
&#xD;
          -  Permanent pacemaker or defibrillator leads in the right heart&#xD;
&#xD;
          -  Severe left ventricular impairment (&lt;25%)&#xD;
&#xD;
          -  Indication for cardiac resynchronisation therapy (CRT)&#xD;
&#xD;
          -  Right atrial pressure â‰¥15mmHg&#xD;
&#xD;
          -  Life expectancy &lt;1 year&#xD;
&#xD;
          -  Severe renal impairment (eGFR&lt;15)&#xD;
&#xD;
          -  Contraindication to CMR&#xD;
&#xD;
          -  Contraindication to adenosine&#xD;
&#xD;
          -  Ischaemia isolated to inferior wall&#xD;
&#xD;
          -  Ongoing participation in a separate interventional study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rasha Al-Lamee, PhD MRCP</last_name>
    <phone>020 7594 5735</phone>
    <email>r.al-lamee13@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Foley, MBBS MRCP</last_name>
    <phone>020 7594 5735</phone>
    <email>m.foley@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Basildon and Thurrock Hospitals NHS Foundation Trust</name>
      <address>
        <city>Basildon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Davies, PhD</last_name>
      <email>john.davies@btuh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter O'Kane</last_name>
      <email>peter.o'kane@rbch.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rasha Al-Lamee, PhD MRCP</last_name>
      <phone>02075945735</phone>
      <email>rasha.al-lamee@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Michael Foley, MBBS MRCP</last_name>
      <phone>02075945735</phone>
      <email>m.foley@nhs.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St George's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Spratt, MbChB MD</last_name>
      <email>james.spratt@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonathan Hill</last_name>
      <email>jmhill@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>May 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

